Amgen highlights survival benefits of Vectibix for colorectal cancer patients

Amgen has announced results from new retrospective analyses of key studies of its drug Vectibix, further underlining the benefits it can offer to colorectal cancer patients.

Retrospective analysis of the PEAK study in metastatic colorectal cancer patients with RAS wild-type primary tumours of left-sided origin showed that those treated with Vectibix plus FOLFOX6 chemotherapy as a first-line treatment achieved 43.4 months median overall survival, an increase of 11.4 months compared to FOLFOX6 plus bevacizumab.

Additionally, data from the PRIME study showed Vectibix plus FOLFOX4 increased overall survival by 6.7 months in the same patient population when compared to FOLFOX4 alone.

The PEAK and PRIME studies also revealed that patients with RAS wild-type tumours of left-sided origin receiving Vectibix plus FOLFOX chemotherapy achieved better progression-free survival results.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "Tumour sidedness is a surrogate for differences in tumour biology and mutation load, potentially providing physicians with another means to help inform the treatment decisions for patients with metastatic colorectal cancer."

Amgen's research indicates that approximately 80 percent of tumours originate in the left side of the colon, while those originating in the right side of the colon are currently associated with a poorer prognosis.  

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.